Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eczema drug shows promise in Mid-Stage trial

NCT ID NCT07277660

Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 7 times

Summary

This study tests a new medicine called galvokimig in 160 adults with moderate-to-severe atopic dermatitis (eczema). The goal is to see if different doses can reduce skin redness, itching, and rash better than a placebo. Participants will receive injections and be monitored for 16 weeks to check safety and effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant must be aged greater than or equal (≥)18 years at the time of signing the informed consent * Participant has chronic atopic dermatitis (AtD) (according to American Academy of Dermatology Consensus Criteria) that has been present for at least ≥1 year prior to initiating the study (ie, signing of the informed consent form \[ICF\]) and with: 1. validated Investigator Global Assessment (vIGA) score ≥3 at Screening and Baseline 2. Eczema Area and Severity Index (EASI) score ≥16 at both Screening and Baseline 3. Peak Pruritus Numerical Rating Scale (PP-NRS) score of ≥4 at both Screening and Baseline 4. ≥10% body surface area (BSA) of AtD involvement at both Screening and Baseline 5. Documented recent history (within 6 months prior to Screening) of inadequate response to treatment with topical medications, or study participants for whom topical treatments are otherwise medically inadvisable (eg, due to important side effects or safety risks) and who are candidates for systemic therapy Exclusion Criteria: * Participant has any history or presence of any medical or psychiatric condition, physical examination finding, laboratory test result, or electrocardiogram (ECG) signal that, in the opinion of the investigator, could constitute a risk when taking the study intervention; or interfere with the interpretation of data and could jeopardize or would compromise the study participant's ability to participate in this study * Active dermatologic conditions that may confound the diagnosis of AtD or would interfere with assessment of treatment, such as but not limited to scabies, seborrheic dermatitis, cutaneous lymphoma, ichthyosis, psoriasis, active allergic or irritant contact dermatitis * Presence or family history (first degree) of inflammatory bowel disease (includes Crohn's disease and ulcerative colitis) * History of chronic or recurrent infections, or a serious or life-threatening infection within the 6 months prior to the Baseline (including herpes zoster) as judged by the investigator * Participants are not permitted to enroll into the study if they meet tuberculosis (TB) exclusion criteria * Previous treatment with galvokimig * Participant has relevant safety events to one or more interleukin (IL)-13 biologic response modifiers (ie, dupilumab, tralokinumab and lebrikizumab) that resulted in discontinuation and change of treatment * All systemic therapies (other than biologics), topical therapies and other treatments for AtD must be discontinued at least 4 weeks prior to Baseline * Treatment with biologic agents must discontinued at least 3 months prior to baseline

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites in 6 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Atd002 21001

    ACTIVE_NOT_RECRUITING

    Habikino, Japan

  • Atd002 21002

    RECRUITING

    Nagasaki, Japan

  • Atd002 21004

    ACTIVE_NOT_RECRUITING

    Tachikawa-shi, Japan

  • Atd002 21005

    ACTIVE_NOT_RECRUITING

    Sakai, Japan

  • Atd002 21006

    ACTIVE_NOT_RECRUITING

    Yokohama, Japan

  • Atd002 21007

    ACTIVE_NOT_RECRUITING

    Nagoya, Japan

  • Atd002 21008

    ACTIVE_NOT_RECRUITING

    Sapporo, Japan

  • Atd002 41001

    ACTIVE_NOT_RECRUITING

    Pleven, Bulgaria

  • Atd002 41002

    ACTIVE_NOT_RECRUITING

    Sevlievo, Bulgaria

  • Atd002 41003

    RECRUITING

    Sofia, Bulgaria

  • Atd002 41004

    ACTIVE_NOT_RECRUITING

    Lovech, Bulgaria

  • Atd002 41005

    ACTIVE_NOT_RECRUITING

    Sofia, Bulgaria

  • Atd002 41006

    ACTIVE_NOT_RECRUITING

    Sofia, Bulgaria

  • Atd002 41007

    ACTIVE_NOT_RECRUITING

    Plovdiv, Bulgaria

  • Atd002 42001

    ACTIVE_NOT_RECRUITING

    Prague, Czechia

  • Atd002 42002

    ACTIVE_NOT_RECRUITING

    Náchod, Czechia

  • Atd002 42003

    ACTIVE_NOT_RECRUITING

    Prague, Czechia

  • Atd002 42004

    ACTIVE_NOT_RECRUITING

    Prague, Czechia

  • Atd002 42005

    ACTIVE_NOT_RECRUITING

    Prague, Czechia

  • Atd002 43001

    ACTIVE_NOT_RECRUITING

    Bad Bentheim, Germany

  • Atd002 43002

    RECRUITING

    Frankfurt, Germany

  • Atd002 43003

    RECRUITING

    Lübeck, Germany

  • Atd002 43004

    ACTIVE_NOT_RECRUITING

    Leipzig, Germany

  • Atd002 43005

    RECRUITING

    Dresden, Germany

  • Atd002 43007

    ACTIVE_NOT_RECRUITING

    Mahlow, Germany

  • Atd002 44001

    ACTIVE_NOT_RECRUITING

    Debrecen, Hungary

  • Atd002 44003

    RECRUITING

    Budapest, Hungary

  • Atd002 45001

    ACTIVE_NOT_RECRUITING

    Katowice, Poland

  • Atd002 45002

    ACTIVE_NOT_RECRUITING

    Warsaw, Poland

  • Atd002 45003

    ACTIVE_NOT_RECRUITING

    Krakow, Poland

  • Atd002 45004

    ACTIVE_NOT_RECRUITING

    Lodz, Poland

  • Atd002 45005

    ACTIVE_NOT_RECRUITING

    Sosnowiec, Poland

  • Atd002 45006

    ACTIVE_NOT_RECRUITING

    Warsaw, Poland

  • Atd002 45007

    ACTIVE_NOT_RECRUITING

    Krakow, Poland

  • Atd002 45008

    ACTIVE_NOT_RECRUITING

    Wroclaw, Poland

  • Atd002 45009

    ACTIVE_NOT_RECRUITING

    Tarnów, Poland

  • Atd002 45010

    ACTIVE_NOT_RECRUITING

    Krakow, Poland

  • Atd002 45011

    ACTIVE_NOT_RECRUITING

    Chorzów, Poland

  • Atd002 45013

    ACTIVE_NOT_RECRUITING

    Lodz, Poland

  • Atd002 45014

    ACTIVE_NOT_RECRUITING

    Krakow, Poland

  • Atd002 46003

    ACTIVE_NOT_RECRUITING

    Salford, United Kingdom

  • Atd002 46004

    ACTIVE_NOT_RECRUITING

    London, United Kingdom

  • Atd002 46006

    RECRUITING

    Sheffield, United Kingdom

  • Atd002 46007

    RECRUITING

    London, United Kingdom

  • Atd002 51002

    ACTIVE_NOT_RECRUITING

    Edmonton, Canada

  • Atd002 51003

    ACTIVE_NOT_RECRUITING

    Vancouver, Canada

  • Atd002 51006

    ACTIVE_NOT_RECRUITING

    Hamilton, Canada

  • Atd002 51007

    ACTIVE_NOT_RECRUITING

    Toronto, Canada

  • Atd002 52001

    RECRUITING

    Troy, Michigan, 48084, United States

  • Atd002 52003

    ACTIVE_NOT_RECRUITING

    Miami, Florida, 33133, United States

  • Atd002 52004

    ACTIVE_NOT_RECRUITING

    Sugar Land, Texas, 77479, United States

  • Atd002 52005

    ACTIVE_NOT_RECRUITING

    Dallas, Texas, 75230, United States

  • Atd002 52007

    ACTIVE_NOT_RECRUITING

    Miami, Florida, 33126, United States

  • Atd002 52008

    ACTIVE_NOT_RECRUITING

    Santa Monica, California, 90403, United States

  • Atd002 52009

    ACTIVE_NOT_RECRUITING

    Troy, Michigan, 48084, United States

  • Atd002 52010

    ACTIVE_NOT_RECRUITING

    Omaha, Nebraska, 68144, United States

  • Atd002 52011

    ACTIVE_NOT_RECRUITING

    Frisco, Texas, 75034, United States

  • Atd002 52012

    ACTIVE_NOT_RECRUITING

    New Albany, Indiana, 47150, United States

  • Atd002 52013

    ACTIVE_NOT_RECRUITING

    Boca Raton, Florida, 33486, United States

  • Atd002 52014

    ACTIVE_NOT_RECRUITING

    Bowling Green, Kentucky, 42104, United States

  • Atd002 52015

    ACTIVE_NOT_RECRUITING

    Savannah, Georgia, 31419, United States

  • Atd002 52016

    ACTIVE_NOT_RECRUITING

    Frisco, Texas, 75033, United States

  • Atd002 52017

    ACTIVE_NOT_RECRUITING

    Chicago, Illinois, 60657, United States

  • Atd002 52018

    ACTIVE_NOT_RECRUITING

    Wheaton, Illinois, 60189, United States

  • Atd002 52019

    ACTIVE_NOT_RECRUITING

    Philadelphia, Pennsylvania, 19114, United States

  • Atd002 52020

    ACTIVE_NOT_RECRUITING

    The Bronx, New York, 10455, United States

  • Atd002 52021

    ACTIVE_NOT_RECRUITING

    Oceanside, California, 92056, United States

  • Atd002 52022

    ACTIVE_NOT_RECRUITING

    New York, New York, 10029-6574, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.